Another example of a large, multi-center, randomized trial assessing SGLT2 inhibition is DECLARE-TIMI58, where 17,160 patients with type-2 diabetes were given either dapagliflozin or a placebo. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.